Table 2.
Overview of ISP results and statistical values
| Drug | Stimulation region | Pre-ISP ± SEM | Post-ISP ± SEM | t | p | d ′ |
|---|---|---|---|---|---|---|
| Placebo | Motor cortex | 73.08 ± 8.89% | 75.15 ± 9.45% | 0.338 | 0.742 | −0.102 |
| DLPFC | 77.59 ± 7.52% | 73.56 ± 6.20% | 0.787 | 0.449 | 0.238 | |
| L-DOPA | Motor cortex | 72.78 ± 8.55% | 71.54 ± 9.89% | 0.143 | 0.889 | 0.041 |
| DLPFC | 85.78 ± 7.53% | 83.55 ± 6.69% | 0.220 | 0.830 | 0.063 | |
| Baclofen | Motor cortex | 72.94 ± 8.35% | 60.18 ± 7.43% | 3.639 | 0.0039 | 1.050 |
| DLPFC | 87.43 ± 10.39% | 73.87 ± 6.58% | 1.349 | 0.204 | 0.390 | |
| Rivastigmine | Motor cortex | 70.83 ± 8.19% | 75.57 ± 12.12% | −0.472 | 0.646 | −0.136 |
| DLPFC | 79.63 ± 8.02% | 88.87 ± 9.14% | −1.165 | 0.268 | −0.336 | |
| Dextromethorphan | Motor cortex | 77.75 ± 9.33% | 71.37 ± 10.98% | 0.595 | 0.575 | 0.179 |
| DLPFC | 82.75 ± 10.02% | 98.52 ± 11.85% | −1.369 | 0.198 | −0.395 |